Targeting Leukemic Stem Cells in Marrow Could Stave Off TKI Resistance

New research suggests that a novel, investigative drug could help alleviate some of the resistance to tyrosine kinase inhibitor treatment seen in chronic myeloid leukemia (CML). The drug, a pan-BCL2 inhibitor called sabutoclax, could sensitize malignant leukemic stem cells in the bone marrow niche to TKI treatment.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news